Activation of nuclear factor-κB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6354-6363

  Jin, Fengshuo ^a,c   Liu, Xiangguo ^a   Zhou, Zhongmei ^a   Yue, Ping ^a   Lotan, Reuben ^b   Khuri, Fadlo R ^a   Chung, Leland W K ^a   Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; CASPASE 3; CASPASE 8; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DIMETHYL SULFOXIDE; DNA FRAGMENT; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HELENALIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RETINOID;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 8; CASPASES; CELL LINE, TUMOR; HUMANS; I-KAPPA B PROTEINS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RETINOIDS; SESQUITERPENES; UP-REGULATION;

EID: 22244477083     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4061     Document Type: Article

References (48)

1. Kurcharczak J, Simmons MJ. Fan Y, Gelinas C. To be, or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003;22:8961-82.
2. Aggarwal BB. Apoptosis and nuclear factor-κB: a tale of association and dissociation. Biochem Pharmacol 2000;60:1033-9.
3. Ravi R, Bedi GC, Engstrom LW, et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat Cell Biol 2001;3:409-16.
4. Sumitomo M, Tachibana M, Nakashima J, et al. An essential role for nuclear factor κB in preventing TNF-α-induced cell death in prostate cancer cells. J Urol 1999;161:674-9.
5. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutive and TNF α-induced activation of NF-κB and sensitizes human prostate carcinoma DU145 cells to TNF α-induced apoptosis. Oncogene 2002;21:1759-67.
6. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20:7597-609.
7. Shimada K, Nakamura M, Ishida E., Kishi M, Yonehara S, Konishi N. Contributions of mitogen-activated protein kinase and nuclear factor κB to N-(4-hydroxyphenyl) retinamide-induced apoptosis in prostate cancer cells. Mol Carcinog 2002;35:127-37.
8. Gunawardena K, Murray DK, Swope KE, Meikle AW. Inhibition of nuclear factor κB induces apoptosis following treatment with tumor necrosis factor α and an antioxidant in human prostate cancer cells. Cancer Detect Prev 2002;26:229-37.
9. Flynn V Jr, Ramanitharan A, Moparty K, et al. Adenovirus-mediated inhihition of NF-κB confers chemo-sensitization and apoptosis in prostate cancer cells. Int J Oncol 2003;23:317-23.
10. Gasparian AV, Yao YJ, Lu J, et al. Selenium compounds inhibit IκB kinase (IKK) and nuclear factor-κB (NF-κB) in prostate cancer cells. Mol Cancer Ther 2002;1:1079-87.
11. Uzzo RG, Leavis P, Hatch W, et al. Zinc inhibits nuclear factor-κB activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res 2002;8:3579-83.
12. Kimura K, Gelmann EP. Propapoptotic effects of NF-κB in LNCaP prostate cancer cells lead to serine protease activation. Cell Death Differ 2002;9:972-80.
13. Lin KI, Lee SII, Narayanan R, Baraban JM, Hardwick JM, Ratan RR. Thiol agents and Bcl-2 identify an alphavinis-induced apoptotic pathway that requires activation of the transcription factor NF-κB. J Cell Biol 1995:131:1149-61.
14. Ilammond LA, Brown G, Keedwell RG, Durham J, Chandraratna RA. The prospects of retinoids in the treatment of prostate cancer. Anticancer Drugs 2002;13:781-90.
15. Zhang XK. Vitamin A and apoptosis in prostate cancer. Endocr Relat Cancer 2002;9:87-102.
16. Fontana JA, Rishi AK. Classical and novel retinoids: their targets in cancer therapy. Leukemia 2002;16:463-72.
17. Schadendorf D, Kern MA, Artuc M, et al. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol 1996;135:1889-98.
18. Langdon SP, Rabiasz GJ, Ritchie AA, et al. Growth-inhibitory effects nf the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo. Cancer Chemother Pharmacol 1998;42:429-32.
19. Sun SY, Yue P, Chen X, Hong WK, Lotan R. The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. Cancer Res 2002;62:2430-6.
20. 1 arrest in their normal counterparts. J Cell Physiol 2001;186:24-34.
21. Sun SY, Vue P, Lotan R. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 2000;19:4513-22.
22. Zhao X, Spanjaard RA. The apoptotic action uf the retinoid CD437/AIIPN: diverse effects, common basis. J Biomed Sci 2003;10:44-9.
23. Pfahl M, Piedrafita FJ. Retinoid targets for apoptosis induction. Oncogene 2003;22:9058-62.
24. Ponzanelli I, Gianni M, Giavazzi R, et al. Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxy-phenyl]-2- naphthalene carboxylic acid. Blood 2000;95:2672-82.
25. Bayon Y, Ortiz MA, Lopez-Hernandez FJ, et al. Inhibition of IκB kinase by a new class of retinoid-related anticancer agents that induce apoptosis. Mol Cell Biol 2003;23:1061-74.
26. Lyss G, Knorre A, Schmidt TJ, Pahl HL, Merfort I. The anti-inflammatory sesqiriterpene lactone helenalin inhibits the transcription factor NF-κB by directly targeting p65. J Biol Chem 1998;273:33508-16.
27. Thalmann GN, Sikes RA, Wu TT, et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000;44:91-103.
28. Sun SY, Yue P, Wu GS, et al. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999;18:2357-65.
29. Sun SY, Yue P, Dawson MI, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 1997;57:4931-9.
30. Mayo MW, Denlinger CE, Broad RM, et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptinnal activation of NF-κB through the Akt pathway. J Biol Chem 2003;278:18980-9.
31. Pollock R, Treisman R. A sensitive method for the determination of protein-DNA binding specificities. Nucleic Acid Res 1990;18:6197-204.
32. Sinha SK, Chaudhary PM. Induction of apoptosis by X-linked ectodermal dysplasia receptor via a caspase 8-dependent mechanism. J Biol Chem 2004;279:41873-81.
33. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002;419:395-9.
34. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor upregulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004;96:1769-80.
35. Wajant II. Targeting the FLICE inhibitory protein (FLIP) in cancer therapy. Mol Interv 2003;3:124-7.
36. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-9.
37. Debatin KM, Krammer PII. Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66.
38. Hehner SP, Heinrich M, Bork PM, et al. Sesquiterpene liictones specifically inhibit activation of NF-κB by preventing the degradation of IκB-α and IκB-β. J Biol Chem 1998;273:1288-97.
39. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor-κB during doxorubicin-induced apoptosis in endothclial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J 2002;367:729-40.
40. Andriollo M, Favier A, Guiraud P. Adriamycm activates NF-κB in human lung carcinoma cells by IκB degradation. Arch Biochem Biophys 2003;413:75-82.
41. Bian X, McAllister-Lucas LM, Shao F, et al. NF-κB activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 2001;276:48921-9.
42. Das KC, White CW. Activation of NF-κB by antineoplastic agents. Hole of protein kinase C. J Biol Chem 1997;272:14914-20.
43. Tabata M, Tabata R, Grabowski OK, Bukowski RM, Ganapathi MK, Ganapathi R. Roles of NF-κB and 26S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human non small cell lung carcinoma. J Biol Chem 2001;276:8029-36.
44. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000;60:4426-32.
45. Sato K, Taniguchi T, Suzuki M, Shinohara F, Takada H, Rikiishi H. Dual role of NF-κB in apoptosis of THP-1 cells during treatment with etoposide and lipopolysaccharide. Leuk Res 2004;28:63-9.
46. Spalding AC, Jotle RM, Scheinman RI, et al. TRAIL and inhibitors uf apoptosis are opposing determinants for NF-κB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene 2002;21:260-71.
47. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
48. Sheikh MS, Huang Y. Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets 2004;4:97-104.